Safety and effectiveness of oral medium to high dose blonanserin in patients with schizophrenia: subgroup analysis from a prospective, multicenter, post-marketing surveillance study in mainland China

BACKGROUND: Blonanserin (BNS) had been undergoing post-market surveillance (PMS) since September 2018. Using the surveillance data, we did this analysis to assess the safety and effectiveness of different doses of BNS to explore a sufficient dose range of BNS in Chinese patients with schizophrenia (...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yuan, Ge, Hongmin, Wang, Xijin, Liu, Xuejun, Li, Keqing, Wang, Gang, Yang, Xiaodong, Deng, Huaili, Sun, Meijuan, Zhang, Ruiling, Chen, Jindong, Cai, Duanfang, Sang, Hong, Liu, Xianglai, Zhan, Guilai, Zhao, Guijun, Li, Haiyun, Xun, Zhiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557194/
https://www.ncbi.nlm.nih.gov/pubmed/37803378
http://dx.doi.org/10.1186/s12991-023-00467-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557194/
https://www.ncbi.nlm.nih.gov/pubmed/37803378
http://dx.doi.org/10.1186/s12991-023-00467-w

Ejemplares similares